Karen Brunke
Acting CEO,
Magdalena Biosciences
United States
Dr. Brunke is the Acting CEO of Magdalena Biosciences, Inc. She has over 30 years of scientific, operational, clinical, senior executive, and corporate development managerial experience with large and small biotechnology companies. She is also currently the Executive Vice President of Corporate and Business Development at Jaguar Health, Inc. (NASDAQ: JAGX) and serves on the BOD of CytoDyn, Inc. (CYDY). Previously, Dr. Brunke was part of the executive team that merged Mercator Genetics Inc. with Progenitor, a subsidiary of Interneuron Pharmaceuticals, in 1999 and helped take the resulting company public. Dr. Brunke was Chief Operating Officer of Anexus Pharmaceuticals, a subsidiary of the Japanese public company MediBic, responsible for in- and out-licensing assistance for Japanese companies, and was founding Chief Executive Officer of Cardeus Pharmaceuticals, a neuroscience company. She also was Research Director for the scientific team creating GMOs underpinning the $3 B annual sales of Sandoz Seeds/Syngenta Seeds. Dr. Brunke received her BA in Biochemistry as well as a Ph.D. in Microbiology from the University of Pennsylvania and did postdoctoral studies at the Institute for Cancer Research in Fox Chase.
Suffix
Not Applicable
Sessions
-
10-Feb-2025Magdalena Biosciences, Inc.
)
){kind=logo}
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}